Date: Jan 21, 2017 09:00 AM - 10:00 AM
Registration closes on Jan 21, 2017 08:50 AM
The disclosure policies of the SIUE School of Pharmacy Office of Continuing Professional Education requires all persons in a position to control content to disclose any relevant financial relationships with commercial interests. If a conflict is identified, the Office of Professional Continuing Education will initiate a process for resolving the conflict. The existence of relationships does not necessarily imply bias or lessen the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The persons required to disclose conflicts include all course faculty, the SIUE CPE administrator, all activity planners and all reviewers. The relevant commercial financial relationships or affiliations must have occured over the past 12 months.
The participant must provide the correct NABP ePID number/DOB combination in their electronic profile. All CPE evaluations must be completed within 60 days of completing the activity. It is the participant's responsibility to check that their credit records are correct within the 60 day period after completion of the activity. Log in to CPE Monitor at www.mycpemonitor.net to view a list of all ACPE-accredited activities you have taken. Any discrepancies must be resolved with the CPE Provider directly and in a timely manner.
Requirements for CE Credit
SIUE School of Pharmacy will transmit pharmacist activity completions to CPE Monitor. To view a list of all ACPE-accredited activities you have taken, log in to CPE Monitor at www.mycpemonitor. For information on the eligibility of this continuing education credit toward meeting your CME/CE requirements, please consult your professional association or state licensing board.
For questions regarding CME/CE activities, please email email@example.com
It is the responsibility of the participant to ensure that all course credits earned are present in their cpe monitor profile within the timeframe specified by ACPE.
Registration closes on Jan 21, 2017
at 08:50 AM
- Describe the impact of renal cell carcinoma on the United States population
- Compare and contrast the roles of VEGF and mTOR targeted therapies in the management of advanced renal cell carcinoma
- Recommend sequence of systemic therapies for the management of advanced renal cell carcinoma
- Counsel patients on the safety of systemic therapies for the management of advanced renal cell carcinoma
Keith Hecht, Pharm.D., BCOP
Brief Bio : Dr. Hecht is a clinical associate professor in the Department of Pharmacy Practice. Before joining SIUE, Dr. Hecht served as an assistant professor of Pharmacy Practice at the University of Southern Nevada College of Pharmacy. Dr. Hecht received his B.S. (2000) and Doctorate of Pharmacy (2001) from St. Louis College of Pharmacy. Subsequently, he completed a pharmacy practice residency and an oncology specialty residency at the University of Kentucky Chandler Medical Center, where he also obtained a certificate for scholarship of teaching and learning. He has been a board-certified oncology pharmacy specialist since 2004. In addition to his faculty appointment at SIUE, Dr. Hecht also provides clinical services in inpatient oncology at St. John’s Mercy Medical Center. Dr. Hecht is interested in various areas of oncology pharmacy practice including supportive care, patient education, and optimizing patient adherence with oncology medications. His research areas of interest include growth factor support, anti-infective use, and regimen optimization in oncology patients.